Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

SIMPLE SUMMARY: The treatment scenario of metastatic renal cell carcinoma has drastically changed in recent years, with the advent of immunotherapy. Since 2015 immune-checkpoint inhibitors, either alone or in combination with other compounds, are constantly enriching the treatment scenario, with a d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Mollica, Veronica, Brocchi, Stefano, Dall’Olio, Filippo Gustavo, Marcolin, Laura, Paccapelo, Alexandro, Santoni, Matteo, Rizzo, Alessandro, Montironi, Rodolfo, Golfieri, Rita, Massari, Francesco, Ardizzoni, Andrea
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8304626/
https://ncbi.nlm.nih.gov/pubmed/34298702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143492
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi